No abstract available
MeSH terms
-
Cardiology / organization & administration
-
Cardiovascular Agents* / adverse effects
-
Cardiovascular Agents* / therapeutic use
-
Cardiovascular Diseases* / drug therapy
-
Cardiovascular Diseases* / mortality
-
Cardiovascular Diseases* / prevention & control
-
Cholesterol / blood
-
Consensus
-
Enzyme Inhibitors* / adverse effects
-
Enzyme Inhibitors* / therapeutic use
-
Humans
-
Hyperlipoproteinemia Type II* / drug therapy
-
Hyperlipoproteinemia Type II* / mortality
-
Hyperlipoproteinemia Type II* / prevention & control
-
PCSK9 Inhibitors*
-
Practice Guidelines as Topic
-
Risk Factors
Substances
-
Cardiovascular Agents
-
Enzyme Inhibitors
-
PCSK9 Inhibitors
-
Cholesterol
-
PCSK9 protein, human